Environmental lead exposure and urate excretion in the general population

American Journal of Medicine

Volumn 113, Issue 7, 2002, Pages 563-568

  Lin, Ja Liang ^a   Tan, Dan Tzu ^a   Ho, Huei Hong ^a   Yu, Chun Chen ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EDETIC ACID; LEAD; URIC ACID;

ADULT; AGE; AGED; ARTICLE; BODY BURDEN; BODY MASS; CHELATION THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; ENVIRONMENTAL EXPOSURE; FEMALE; GOUT; HUMAN; INDUSTRIAL WORKER; KIDNEY FUNCTION; LEAD BLOOD LEVEL; MALE; NORMAL HUMAN; OCCUPATIONAL EXPOSURE; POLLUTANT; POLLUTION; POPULATION; PRIORITY JOURNAL; PROTEIN INTAKE; SEX; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL;

ADULT; AGED; BODY BURDEN; CHELATING AGENTS; CROSS-SECTIONAL STUDIES; EDETIC ACID; ENVIRONMENTAL EXPOSURE; FEMALE; GOUT; HUMANS; LEAD; MALE; MIDDLE AGED; REFERENCE VALUES; TREATMENT OUTCOME; URIC ACID;

EID: 0036852393     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01296-2     Document Type: Article

References (33)

1. Johnson R.J., Kivlighn S.D., Kim Y.G., et al. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis. 33:1999;225-234.
2. Campion E.W., Glynn R.J., Delabry L.O. Asymptomatic hyperuricemia risks and consequence in the Normative Aging Study . Am J Med. 82:1987;421-426.
3. Bernard B.P., Becker C.E. Environmental lead exposure and the kidney. Clin Toxicol. 26:1988;1-34.
4. Wedeen R.P., Mallik K., Batumann V. Detection and treatment of occupational lead nephropathy. Arch Intern Med. 139:1979;53-57.
5. Boss G.R., Seegmiller J.E. Hyperuricemia and gout. N Engl J Med. 300:1979;1459-1468.
6. Pirkle J.L., Schwartz J., Landis J.R., Harlan W.R. The relationship between blood lead and blood pressure and its cardiovascular risk implications. Am J Epidemiol. 121:1985;246-258.
7. Staessen J.A., Lauwerys R.R., Buchet J., et al. Impairment renal function with increasing blood lead concentrations in the general population. N Engl J Med. 327:1992;151-156.
8. Lin J.L., Tan D.T., Hsu K.H., Yu C.C. Environmental lead exposure and progressive renal insufficiency. Arch Intern Med. 161:2001;264-271.
9. Pocock S.J., Shaper A.G., Ashby D., et al. Blood lead concentrations, blood pressure, and renal function. BMJ. 289:1984;872-874.
10. Campbell B.C., Beattie A.D., Moore M.R., et al. Renal insufficiency associated with excessive lead exposure. BMJ. 1:1977;482-485.
11. Shadick N.A., Kim R., Weiss S., et al. Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men the Nomative Aging Study . J Rheumatol. 27:2000;1708-1712.
12. Baker M.D., Johnston J.R., Maclatchy A.E., Buzuidenhout B.N. The relationship of serum uric acid to subclinical blood lead. Rheumatol Rehabil. 20:1981;208-210.
13. Lin J.L., Lim P.S. Elevated lead burden in Chinese patients without occupational lead exposure. Minerva Electrolyte Metab. 18:1992;1-5.
14. Lin J.L., Huang P.T. Body lead stores and urate excretion in men with chronic renal disease. J Rheumatol. 21:1994;705-709.
15. Wallace S.L., Robinson H., Masi A.T., et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 20:1977;895-900.
16. Isaksson B. Urinary nitrogen output as a validity test in dietary surveys. Am J Clin Nutr. 33:1980;4-5.
17. Spencer K. Analytic reviews in clinical biochemistry the estimation of creatinine . Ann Clin Biochem. 23:1986;1-25.
18. James D.R., Price C.P. Problem associated with the measurement of uric acid using two enzyme-mediated reaction systems. Ann Clin Biochem. 21:1984;405-410.
19. Rieselbach R.E., Sorensen L.B., Shelp W.D., Steele T.H. Diminished renal urate secretion per nephron as a basis for primary gout. Ann Intern Med. 73:1970;359-366.
20. Behringer D., Craswell P., Mohl C., et al. Urinary lead excretion in uremia patients. Nephron. 42:1986;323-329.
21. Lin J.L., Lim P.S. Disappearance of immune deposits with EDTA chelation therapy in a case of Ig A nephropathy. Am J Nephrol. 12:1992;457-460.
22. Lin J.L., Yu C.C., Lin-Dan D.T., Ho H.H. Lead chelation therapy and urate excretion in patients with chronic renal diseases and gout. Kidney Int. 60:2001;266-271.
23. Liou S.H., Wu T.N., Chiang H.C., et al. Three-year survey of blood lead levels in 8828 Taiwanese. Int Arch Occup Environ Health. 68:1996;80-87.
24. Miranda-Caris E., Mateos F.A., Sanz A.G., et al. Purine metabolism in patients with gout the role of lead . Nephron. 75:1997;327-335.
25. Batuman V. Lead nephropathy, gout, and hypertension. Am J Med Sci. 305:1993;241-247.
26. Wedeen R.P., Batuman V., Landy E. Safety of EDTA lead mobilization test. Environ Res. 30:1983;58-62.
27. Lin J.L., Ho H.H., Yu C.C. Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency - a randomized, clinical trial. Ann Intern Med. 130:1999;7-13.
28. Reynolds P.R., Knapp M.J., Baraf H.S., Holmes E.W. Moonshine and lead relationship to the pathogenesis of hyperuricemia in gout . Arthritis Rheum. 26:1983;1057-1064.
29. Khalil-Manesh F., Gonick H.C., Cohen A., et al. Experimental model of lead nephropathy II. Effect of removal from lead exposure and chelation treatment with dimercaptosuccinic acid (DMSA) . Environ Res. 58:1992;35-54.
30. Emmerson B.T., Mirosch W., Douglas J.B. The relative contribution of tubular re-absorption and secretion to urate excretion in lead nephropathy. Aust N Z J Med. 1:1971;353-362.
31. Luscher T.F., Bock H.A., Yang Z., Diederich D. Endothelial-derived relaxing and contracting factors prospective in nephrology . Kidney Int. 39:1991;575-590.
32. Vaziri N.D., Liang K., Ding Y. Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension. Kidney Int. 56:1999;1492-1498.
33. Ding K., Vaziri N.D., Gonick H.C. Lead induced hypertension. II. Response to sequential infusions of L-arginine, superoxide dismutase, and nitroprusside. Environ Res. 76:1998;107-113.